Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.csbj.2016.05.004 http://scihub22266oqcxt.onion/10.1016/j.csbj.2016.05.004 C4913179!4913179!27358717     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Comput+Struct+Biotechnol+J 2016 ; 14 (ä): 211-22 Nephropedia Template TP {{tp|p=27358717|t=2016. Circulating biomarkers to monitor cancer progression and treatment |pdf=|usr=}}{{27358717}} gab.com Text Circulating biomarkers to monitor cancer progression and treatment JO: Comput Struct Biotechnol J http://www.kidney.de/pget.php?&tw=1&pmid=27358717 #FOAvip Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still, the standard diagnostic approach relies on the analysis of a single tumor sample from a local or metastatic site that is obtained at a given time point. Due to intratumoral heterogeneity and selection of subpopulations in diverse lesions this will provide only a limited characterization of the makeup of the disease. On the other hand, recent developments of nucleic acid sequence analysis allows to use minimally invasive serial blood samples to assess the mutational status and altered gene expression patterns for real time monitoring in individual patients. Here, we focus on cell-free circulating tumor-specific mutant DNA and RNA (including mRNA and non-coding RNA), as well as current limitations and challenges associated with circulating nucleic acids biomarkers. Twit Text FOAVip Circulating biomarkers to monitor cancer progression and treatment ????Comput Struct Biotechnol J http://www.kidney.de/pget.php?&tw=1&pmid=27358717 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27358717 #FOAvip English Wikipedia <ref>{{Cite pmid|27358717}}</ref> Circulating biomarkers to monitor cancer progression and treatment #MMPMID27358717 Rapisuwon S; Vietsch EE; Wellstein A Comput Struct Biotechnol J 2016[]; 14 (ä): 211-22 PMID27358717show ga Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still, the standard diagnostic approach relies on the analysis of a single tumor sample from a local or metastatic site that is obtained at a given time point. Due to intratumoral heterogeneity and selection of subpopulations in diverse lesions this will provide only a limited characterization of the makeup of the disease. On the other hand, recent developments of nucleic acid sequence analysis allows to use minimally invasive serial blood samples to assess the mutational status and altered gene expression patterns for real time monitoring in individual patients. Here, we focus on cell-free circulating tumor-specific mutant DNA and RNA (including mRNA and non-coding RNA), as well as current limitations and challenges associated with circulating nucleic acids biomarkers. äCirculating biomarkers to monitor cancer progression and treatment (epmc).pdf DeepDyve Pubget Overpricing